Abstract
Affected by many factors such as environment and lifestyle change, prostate cancer has become common malignancy in older men. The introduction and widespread adoption of PSA has revolutionized the way prostate cancer is diagnosed and treated. However, the use of PSA has also led to over–diagnosis and overtreatment of prostate cancer resulting in controversy about its use for screening. PSA also has limited predictive accuracy for predicting outcomes after treatment and for making clinical decisions about adjuvant and salvage therapies. Hence, there is an urgent need for novel biomarkers to supplement PSA for detection and management of prostate cancer. In this review, we discuss the traditional and new relevant molecular markers of early diagnosis and prognosis of prostate cancer for clinical diagnosis and prognosis of prostate cancer providing a reference. (Chin J Lab Med, 2015, 38: 657–660) Key words: Prostatic neoplasms; Early diagnosis; Tumor markers, biological; Prognosis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
